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ABSTRACT: Rhomboids are relatively recently discovered
intramembraneserine proteasesthatare conserved through-
outevolution.Theyhaveawiderangeofbiologicalfunctions,
and there is also much speculation about their potential
medicalrelevance.Althoughrhomboidsareweaklyinhibited
by some broad-spectrum serine protease inhibitors, no
potent and speciﬁc inhibitors have been identiﬁed for these
enzymes, which are mechanistically distinct from and evolu-
tionarily unrelated to the classical soluble serine proteases.
Here we report a new biochemical assay for rhomboid function based on the use of quenched ﬂuorescent substrate peptides. We
have developed this assay into a high-throughput format and have undertaken an inhibitor and activator screen of approximately
58,000 small molecules. This has led to the identiﬁcation of a new class of rhomboid inhibitors, a series of monocyclic β-lactams,
which are more potent than any previous inhibitor. They show selectivity, both for rhomboids over the soluble serine protease
chymotrypsin and also, importantly, between diﬀerent rhomboids; they can inhibit mammalian as well as bacterial rhomboids; and
theyareeﬀectivebothinvitroandinvivo.Thesecompoundsrepresentimportanttemplatesforfurtherinhibitordevelopment,which
could have an impact both on biological understanding of rhomboid function and potential future drug development.
I
ntramembrane proteases are relative newcomers to the long
list of proteases that control many biologically and medically
importantcellularprocesses.Thefourfamiliesofintramembrane
proteases comprise site-2 protease,
1 presenilin/γ-secretase,
2
signal peptide peptidase,
3 and rhomboids.
4 The last are intramem-
braneserineproteasesbut,likealltheotherfamilies,areevolutionarily
unrelated to their well-known soluble counterparts. Rhomboids exist
in most sequenced organisms and, despite ignorance of many of
their functions, are already known to participate in processes as
diverse as growth factor signaling,
4-6 mitochondrial function,
7-9
invasion of host cells byapicomplexan parasites,
10-12 andbacter-
ial protein export.
13
One of the key diﬀerences between rhomboids and other
serine proteases is that their active site resides in the lipid bilayer
of membranes, where it is formed by residues contributed by
transmembrane helices.
4,14 This characteristic membrane envi-
ronment establishes biophysical constraints on any potential inhib-
itors and also raises questions about the potential in vivo avail-
abilityofinhibitorsthatmightworkinvitroinadetergentmicelle
system. There are no selective inhibitors yet reported for any
rhomboids, although they are (weakly) inhibited by isocouma-
rins, broad-spectrum inhibitors of serine proteases, and a few
other serine protease inhibitors.
4,15
There are strong incentives to identify selective rhomboid
inhibitors. As research tools, such inhibitors could dramatically
accelerate progress in discovery of the physiological role of
rhomboids, especially in higher organisms such as mammals,
where a genetic approach is slow and diﬃcult. Furthermore,
although they are not yet fully validated disease targets, there are
verystrongindicationsthatrhomboidinhibitorsarelikelytohave
medical utility.
10,12,16-18 Being proteolytic enzymes, it seems
likely that rhomboids are inherently amenable to small molecule
inhibitor screening.
Here we describe the development of a new in vitro assay of
rhomboid activity based on the use of ﬂuorogenic peptides that
spantherecognitionmotifandcleavagesiteofknownsubstrates.
We have further developed this assay into a high-throughput
format and undertakena screen of a library of small molecules to
look for compounds that can inhibit (or activate) rhomboid
activity. This approach has led to the identiﬁcation of a series of
monocyclic β-lactams, the ﬁrst potent and selective rhomboid
inhibitors.
’RESULTS AND DISCUSSION
Development of an in Vitro HTS Rhomboid assay. Pre-
viously reported in vitro assays of rhomboid activity have relied
on incubating detergent-solubilized rhomboids with radioactive
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or non-radioactive protein substrates that encompassed the full
transmembrane domain (TMD) and flanking regions.
15,19-21
These approaches were not readily adaptable to a high-through-
putscreening(HTS)format,soweinvestigatedthepossibility of
generating suitable fluorogenic peptidic substrates for rhom-
boids. Although natural substrates are full-length TMDs, rhom-
boids typically rely on a short recognition motif to determine
cleavage.
19 We therefore tested the ability of short peptides
derived from known rhomboid substrates to be cleaved by
purified bacterial rhomboid proteases in vitro (Figure 1A,B).
HPLC and mass spectrometry analysis showed that synthetic
peptides derived from Providencia stuartii TatA and Drosophila
Gurken were cleaved by P. stuartii and E. coli rhomboids AarA
and GlpG at their natural cleavage sites,
19 albeit with varying
efficiencies (Figure 1B).
Theabilityofrhomboidstocleaveshortpeptidesallowedusto
develop ﬂuorogenic peptide substrates, suitable for high-
throughput screening. We introduced several F€ orster resonance
energytransfer(FRET)donor-acceptorpairsintotheTatAand
Gurkenpeptides,modifyingresiduesthathadbeenshownnotto
be part of the recognition motif of the substrate.
19 We tested a
range of ﬂuorescent dyes (MCA, TAMRA-550, AlexaFluor-647,
Chromis-645),andthebestresultswereobtainedwithaGurken-
derived 15-mer peptide, labeled by the Chromis-645/QSY21
FRET pair at the C-terminus and P5 position, respectively
(Figure 1B). This peptide, KSp21, had better aqueous solubility
than the other FRET-labeled peptides and was the most eﬃcient
ﬂuorogenic substrate for AarA, the rhomboid whose substrate
speciﬁcity is best understood. Progress curves of KSp21 cleavage
by AarA, recorded continuously, were exponential, with a linear
initial phase (Figure 1C). The initial reaction rate increased
linearly with enzyme concentration up to 200 nM (Figure S1A)
and to substrate concentration up to 1 μM (data not shown). At
higher substrate concentrations (>2 μM), KSp21 precipitated,
which prevented us from determining its apparent KM and Vmax.
The solubility of KSp21 was improved by increasing DMSO
concentration in the assay buﬀer, which also enhanced AarA
activity.Inaminiaturizedformat(20μL,384-wellplate)adapted
to HTS, the assay showed an excellent robustness with Z0 score
(statistical indicator of assay reproducibility and sensitivity
22)o f
∼0.8 and a large assay window (Figure 1D). We concluded that
the KSp21-based ﬂuorescent assay, using the rhomboid AarA,
provided an eﬀective platform for a high-throughput screen for
rhomboid inhibitors and activators.
A High-Throughput Screen. A flowchart summarizing the
different steps of the screening campaign is illustrated in
Figure 2A.
PilotandFullScreens. TheKSp21-basedassaywasvalidatedin
a pilot screen of the NINDS collection of 1,040 bioactive
compounds (ICCB Longwood, Harvard Medical School). We
obtained Z0 and Z (Z, the ratio of separation band to the signal
dynamic range, allows the comparison between HTS assays
22)
factors of 0.9 and 0.6-0.8, respectively, and a correlation
between two runs of R
2 = 0.79, with a hit rate of 2.6% (cutoff
Figure1. Fluorescentassaydesign.(A)SchematicrepresentationofrhomboidenzymeAarAcleavinganaturalrhomboidsubstrateorasubstrate-based
peptide. (B) Comparison of AarA activity on three peptides derived from known rhomboid substrates. Rhomboid cleavage sites (asterisks) were
determined by HPLC using peptide standards or MALDI-TOF mass spectrometry. The Gurken-derived peptide was modiﬁed with QSY21 dark
quencherandChromis-645ﬂuorophoretoyieldﬂuorogenicpeptideKSp21.(C)Timecourseofcleavageof1μMKSp21by0.4μMAarA(wtorS150A)
or0.2μMchymotrypsin,at25C.(D) Fluorescentactivityassayadaptedtohigh-throughputscreen(HTS) format.Z0 factor=0.77(signal/background=10,
coeﬃcients of variation = 6%) (see Methods). High control = AarA þ DMSO; low control = no enzyme þ DMSO.327 dx.doi.org/10.1021/cb100314y |ACS Chem. Biol. 2011, 6, 325–335
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as defined in Methods). These statistics strongly validated the
technical quality of the screen.
22 We therefore ran a full primary
screen for inhibitors and activators of AarA from a library of
57,703 molecules, comprising aset of diversecompounds from a
variety of commercial suppliers, twosmall libraries of protease and
kinase inhibitors, and a collection of 2,000 natural compounds
(Analyticon).Compoundswerescreenedat20μM,andAarAacti-
vity was measured by reading fluorescence after stopping the reac-
tion.Thestatisticsofthescreenwerecomparabletothepilot(Z0 =
0.7-0.9), but hitrateswere lower:0.1-0.2%(syntheticmolecules
from the diversity set and focused libraries) and 1.3% (natural
compounds).Interestingly,the53compoundsoftheBiomolclassic
proteaseinhibitorsset(EnzoLifeSciences)didnotgiveanyhits,
except the broad range serine protease inhibitor dichloroisocou-
marin (DCI), a known rhomboid inhibitor. Combined with pre-
vious data that most serine protease inhibitors do not affect rhom-
boids,
4,15 this illustrates that rhomboids are indeed novel
targets.
Hit Confirmation and Counter-screen. We picked 162 com-
pounds from the full screen and confirmed 97% of them in the
same fluorescent assay (Figure 2B,C). In a counter-screen, the
compounds were added postreaction to identify any false posi-
tives that interfere with the assay technology itself (e.g., preci-
pitation-inducers, quenchers, or fluorescent compounds). No
interferingcompoundsweredetected,butonefalseactivatorwas
discarded (data not shown).
IC50/EC50MeasurementsandHitRanking. Asubsetof110hits
that inhibited AarA activity to less than 80% or increased it to
more than 120% of the control and showed liability of 0 to 2
(defined as the frequency that the same compound has been hit
in 16 previous screens of the same library against unrelated
enzymes, thus excluding any obviously promiscuous and unspe-
cific effectors), were characterized further. The potency of these
compounds, including both inhibitors and activators, was deter-
mined by titrating their effect on AarA activity in the fluorescent
assay. Subsequent kinetics revealed that the best activators were
Figure 2. Screening campaign summary. (A) Screen ﬂowchart. (B) Fluorescent signal of 162 initial hits and 190 high controls (DMSO þ AarA), both
denotedbybluediamonds,and32lowcontrols(DMSO,noenzyme),denotedbymagentasquares.DMSOhighcontrolsorinactivecompoundscluster
aroundthe100,000activityunitsmark,inhibitorsarerepresentedbypointsbelow100,000activityunits,andactivatorsareabove.(C)Plotofcorrelation
between initial hits from high-throughput screen and secondary screen; 7 hits (6 false inhibitors, 1 false activator) were not conﬁrmed as they showed
∼100%activityinthesecondscreen(dottedline).(D)ChemicalstructureandapparentIC50valuesofhitsselectedforchemistryoptimization:series1,
bis(triﬂuoromethyl)-amide (bis-CF3), based on compound F1; and series 2, monocyclic β-lactam, based on compound L1.328 dx.doi.org/10.1021/cb100314y |ACS Chem. Biol. 2011, 6, 325–335
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rather weak (EC50 > 0.1 mM), although they did produce up to
30-fold increase in initial rate at the highest concentration tested
(100μM;datanotshown).Despitetheirpotentialinterest,these
activators were not pursued further in this study.
Continuous recording of reaction time courses was used to
rank inhibitors by potency and selectivity over chymotrypsin, an
unrelatedserineprotease.Afterplottingtheinitialrateofreaction
versus compound concentration, we used a 4-parameter logistic
equationtoﬁtourdata(SigmaPlot11,SystatSoftware,Inc.)and
calculate the apparent IC50 values (for simplicity, IC50 hence-
forth). We deﬁned the rhomboid selectivity as the ratio of IC50
against chymotrypsin:IC50 against AarA. Of the 33 inhibitors
with IC50 lower than 30 μM, 15 were synthetic small molecules
(S1-S15, Table S1a) and 18 were natural products or semisyn-
thetic analogues thereof (N1-N18, Table S1b). The natural
products were highly heterogeneous in structure and not amen-
able to chemical optimization or rapid analogue synthesis and so
were not pursued further. The synthetic compounds showed
more promise. Strikingly, ﬁve related bis(triﬂuoromethyl) amide
compounds (“bis-CF3”, preﬁxed “F”, Table S1a and Figure 2D)
formedadistinctiveseriesofinhibitorswithabestIC50e20μM.
Despite their low liability, these initial hits also inhibited chymo-
trypsin (selectivity 0.5-1). We also chose to pursue the mono-
cyclicβ-lactamS12/L1(β-lactamseriespreﬁxed“L”,Figure2D)
which,despitebeingslightlylesspotent(IC50=23μM)thanthe
bis-CF3 compounds, had other encouraging attributes. Despite
inhibitingchymotrypsin(selectivity0.7),L1hadaliabilityofzero
and, apart from cephaloridine (a broad spectrum antibiotic with
cytotoxicity; promiscuous, with liability >2 in our screen), was
uniquely positive among 87 other β-lactams in the library (not
shown). Furthermore, the β-lactam motif present in L1 is a
commonly occurring substructure within the protease inhibitor
ﬁeld, and several are well established as drugs. No other hits
survived the triage process or brief exploratory chemistry to be
selected for further analysis.
Structure-Activity Relationships and Selectivity of Hit
Analogues. In the previous section, we described the selection
of two classes of hit from the primary screen for optimization by
chemical modification: the bis-CF3 compounds (F1-F5) and
themonocyclicβ-lactamL1.Eachwasusedasastartingpointfor
the chemical synthesis of related compounds, which were then
assayed for potency and selectivity against AarA using the fluo-
rescent peptide assay. Subsequently, active hits were validated in
an independent in vitro assay, using a whole membrane protein
substrate instead of a fluorescent peptide, and tested for selec-
tivity against a different rhomboid showing similar substrate
specificity, E. coli GlpG.
19
Bis-CF3 Compounds (F-Series). A total of 108 chemical struc-
tures related to compound F1 were either purchased or synthe-
sized (structures and detailed results in Table S2). Modification
or replacement of the bis(trifluoromethyl) group was attempted
in the following ways: steric replacement of the fluo-
rine atoms (F6, F9-11, F18, F23), “acidity”/chemical modi-
fications (F15, F17, F24-26) including sulfone (F16), classical
protease warhead-type replacements (F8, F12-14, F22), and
moving/deleting the fluorines (F4-5, F7, F19). All of these
changes to the bis-CF3 moiety completely destroyed inhibitory
activity in the fluorescent assay. On the left-hand side of the
molecule (Figure 2D), a range of substituents on the aniline ring
were tolerated (Table S2), but replacement with a pyridine ring
(F27-F29) was not. The best compounds were up to 17-fold
more potent than F1, with IC50 values in the low micromolar
range (F70-F73, Figure 3A). Despite this improvement, the
structure-activity relationship analysis (SAR) of the aniline
portion was rather flat, although the degree of selectivity over
chymotrypsin was significantly improved (Figure 3A, Table S2).
A number of analogues showed a net preference for AarA over
chymotrypsin; among them, compounds F61 and F102 com-
bined good potency with excellent selectivity.
Despite this quite promising improvement of the bis-CF3
compounds,whentestedagainstafull-lengthsubstrateinthegel-
based assay, they raised signiﬁcant concerns. Even at low micro-
molar levels they triggered formation of high molecular weight
protein complexes, combined with the disappearance of the GlpG
(Figure 3B), suggesting that they may cause aggregation of both
enzyme and substrate. Indeed, in the presence of bis-CF3
compounds, substrate aggregated in the absence of enzyme,
and enzyme oligomerized without substrate (data not shown).
Althoughwehavenotinvestigatedtheirmechanismofactionand
their low liability suggests that they might be acting more
speciﬁcally than simply as unselective protein aggregators, these
data were of suﬃcient concern to make us decide not to pursue
this series further.
β-Lactams (L-Series). A total of 58 analogues of β-lactam L1
weresynthesized.Potencyandspecificitydataofkeycompounds
areshowninTable1,andfulldetailsareinSupplementaryTableS3;
we here describe our main conclusions about structure-
activity relationship of this series. As shown in Figure 2D, we
introduced structural changes at all four positions on the β-
lactam ring: the N-substituent (R1), the carbonyl group at C-2
and substituents at C-3 and C-4.
￿ Deletion of the C-2 carbonyl group (L30-31) suppressed
activity, lending support to a mechanism-based mode of
inhibition analogous to other β-lactam serine protease
inhibitors, in which the rhomboid catalytic serine nucleo-
philically attacks the carbonyl group at C-2.
￿ As the N-sulfonyl substituent is predicted to make the
β-lactam ring very reactive, we tested straight-chain ana-
loguestoseewhether thering-openedformwasresponsible
for inhibition. The chloroketones TPCK and TLCK were
inactiveagainstAarA,aswereanaloguesL36-40,implyingthat
the intact β-lactam ring is required for inhibitory activity.
￿ Activity against AarA was suppressed by sulfonyl removal
(L6-7)orreplacementbyurea(L28,L32-33),amide(L8,
L12), or carbamate (L29). L34 was atypical as it retained
activity against AarA despite the amide modiﬁcation.
￿ An N-aryl sulfonyl substituent was essential (L9 inactive),
and lipophilic meta-substituents improved potency (L19-
20, L42, L44-45).
￿ AlthoughthearylringatC-4wasnotrequiredforactivity,its
presence improved potency further, as did small lipophilic
meta-substituents (L44-45). Up to 4-fold gain in potency
against AarA was achieved in L44, by combining meta-
substituents on both aryl rings.
￿ ThemethylgroupatC-3inL1wasnotessential(L2,L4-5,
L14, L16-20, L35, L41-49 and L58), but the parent
(unsubstituted) β-lactam L15 was inactive. Amide deriva-
tives at C-3 reduced (L50-54) or abolished activity
(L55-57).
The β-lactams showed very diﬀerent degrees of selectivity for
rhomboids over chymotrypsin. Out of 58 compounds, 19 stron-
gly preferred chymotrypsin, whereas 6 preferred AarA (L14,
L25-26, L41-42 and L54). Three of these six compounds329 dx.doi.org/10.1021/cb100314y |ACS Chem. Biol. 2011, 6, 325–335
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combined selectivity for AarA with high potency: L25 and L26,
withoutasubstituentatC-4(inactiveonchymotrypsin),andL42
containing a 30- b i a r y ls u l f o n y lg r o u p .T h i sp o t e n t i a lf o rh i g hs e l e c -
tivity in favor of rhomboids is important, as it contrasts with
other known rhomboid inhibitors (of which isocoumarins are
best characterized), which are broad-spectrum serine protease
inhibitors.
23
Inconclusion,thepotencyoftheseβ-lactamsagainstAarAwas
signiﬁcantlyimprovedafterchemicaloptimization,sothatthebest
IC50valuesintheﬂuorescentassaywereequivalenttothatofDCI
(L42, L44-45). Importantly, several β-lactams showed much
better selectivity than DCI for rhomboid over chymotrypsin.
β-Lactams Show High Potency and Selectivity for GlpG.
Unlike the bis-CF3 compounds, the β-lactams did not trigger
substrate or enzyme aggregation in the gel-based assay of GlpG
(Figure4A)orAarA(datanotshown),whichreliesonfull-length
proteinsubstrates.Moreover,manyshowedhighpotencyagainst
GlpG (Figure 4B, Table 1), the best IC50 values being around
0.4-0.8μM.WenotedthatIC50valuesagainstAarAwere2-fold
(L58) to 14-fold (L44) higher (Table 1) in the assay based on
full-length proteins than inthe fluorescent assay; infact, L35 and
L41 did not inhibit AarA at all in this assay, but they did in the
fluorescent peptide assay. The greater resistance to inhibition in
the full-length protein assay presumably reflects the different nature
of the two assays, for example, concentration differences and the
possibly higher affinity for the enzyme of a full-length, TMD-
containing substrate, compared to a short peptide. We are unable
to make a direct comparison of IC50 values against GlpG in the two
assays, as GlpG does not cleave the KSp21 fluorescent peptide.
SAR data show a clear relationship between compound struc-
ture and selectivity between the two rhomboids (Tables 1 and
S3). For instance, certain substituents at C-4 lead to a complete
preference for AarA (L14, L44, and L46) over GlpG. Similarly,
L26 inhibited only AarA, in contrast with L25. On the other
hand, GlpG was preferably targeted if the N-sulfonyl substituent
was replaced (e.g., L8, L29), suggesting that GlpG could tolerate
greater structural changes at this position. Curiously, the re-
synthesizedracemic3,4-cis-L1(relativecisC-3:C-4stereochemistry)
was very potent on GlpG, whereas only the single enantiomer
3S,4S-L1 (HTS hit) was active on AarA. Many β-lactams
Figure 3. In vitro eﬀects of selected bis-CF3 analogues with modiﬁcations of the aniline moiety. (A) Results of ﬂuorescent assay with 600 nM KSp21
peptide and either 100 nM AarA or 37 nM chymotrypsin. (B) Gel-based assay with 320 nM GlpG and 3 μM Gurken chimeric substrate and increasing
concentration (μM) of inhibitor F72. Enzyme (E) substrate (S), and product (P) bands are labeled on the right-hand side of the gel. High molecular
weight protein aggregates appear (vertical line) as inhibitor concentration increases.330 dx.doi.org/10.1021/cb100314y |ACS Chem. Biol. 2011, 6, 325–335
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preferred GlpG over AarA (Table 1): potency was 67- to 302-
fold greater on GlpG than on AarA for L2, L10, L11, L19, L42,
and L58. This net preference is probably also true for L4, L16,
L17, L18, L20, L25, L45, and L47 as AarA retained 71-86% of
DMSOcontrolactivityat100μMcompound(Tables1andS3).
Although we cannot directly compare selectivity of compounds
against GlpG and chymotrypsin, because they are assayed in two
diﬀerent formats, we can deduce high selectivity for GlpG over
chymotrypsin for compounds that already show selectivity for
AarA in the ﬂuorescent assay. Examples are compounds L25
and L42 where a net rhomboid preference over chymotrypsin
was achieved, with a high selectivity for GlpG (Table 1).
To summarize our conclusions based on in vitro analysis of
β-lactam inhibition of rhomboid activity, we found that (i) an
Table 1. Structure-activity Relationship of Key β-Lactam Compounds Described in the Main Text
1Endogenous GlpG activity in E. coli NR698 (see Methods). *72-86% AarA activity at 100 μM compound.331 dx.doi.org/10.1021/cb100314y |ACS Chem. Biol. 2011, 6, 325–335
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intact β-lactam ring is required for activity, suggesting a mecha-
nismofactioninvolvingnucleophilicattackatC-2;(ii)β-lactams
showed greater potency on GlpG than on AarA; (iii) distinct
structural modiﬁcations, summarized in Figure 4C, resulted in
improved potency and diﬀerential selectivity between two bac-
terialrhomboids,aswellasbetweenrhomboidandchymotrypsin
(Table 1). The fact that diﬀerent β-lactams preferentially tar-
geted AarA or GlpG is signiﬁcant as it validates the concept of
developing compounds to target speciﬁc rhomboids.
In Vivo Inhibition by β-Lactams. Intramembrane proteases
normallyworkinthelipidbilayer,butinvitroassaystypically rely
on detergent-solubilized enzyme activity. Are the β-lactam
inhibitors we have identified effective in vivo? We tested whether
any were able to inhibit endogenous GlpG in E. coli. To this end,
theLacYTM2-containingfusionproteinsubstrateofGlpG
21was
expressed in wild-type and GlpG-null strains of E. coli. Upon
induction of substrate expression, only the wild-type strain was
able to cleave LacYTM2, confirming that its processing is
dependent on endogenous GlpG. Initial experiments indicated
no inhibitory activity for the most potent β-lactams, and we
reasoned that they might not be able to penetrate the bacterial
outer membrane, which can form an impermeable barrier to
small molecules. We therefore assayed activity using an E. coli
mutant strain defective in outer membrane biogenesis (NR698)
that has been reported to display increased outer membrane
permeabilitytosmallmolecules.
24Similartothewild-typeE.coli,
NR698 was able to process the LacYTM2 substrate efficiently,
andcleavagewascompletelyabolishedbyglpGdisruption(strain
KS69) (Figure 5A). In this background, seven out of 16 β-
lactams inhibited endogenous GlpG, of which five (L16, L29,
L35,L41,andL42)hadanEC50(definedastheconcentrationof
the compound at which it exerted half of its maximal attainable
effect
25) between 5 and 10 μM (Figure 5B, Table 1).
Finally, we also tested whether selected β-lactams showed
inhibitory activity against a mammalian rhomboid. COS7 cells
were transfected with C-terminally KDEL-tagged mouse rhom-
boid-2(RHBDL2)andGurkensubstrate.Inthiswell-established
assay,
26 the intracellular level of Gurken processing by RHBDL2
was assayed by comparing the ratio of product to substrate band
intensity between the compound and solvent (DMSO) control.
Out of 12 β-lactams tested, some had an eﬀect on protein
expression but did not change the product to substrate band
intensity ratio, whereas three compounds (L25, L29, and L58)
reproducibly displayed detectable inhibition of RHBDL2 in vivo,
Figure 4. In vitro activity of β-lactams: high potency on GlpG and structure-activity relationship (SAR) against AarA and GlpG. (A) Typical gel
showing β-lactam (L35) inhibiting the cleavage of Gurken chimeric substrate (3 μM) by GlpG (320 nM). Enzyme (E), substrate (S), and product (P)
bandsareindicated.(B)BandintensitywasquantiﬁedusingImageJ,andsubstrateconversionwasexpressedas%ofDMSOcontrol.TheapparentIC50
valuesinbracketsweredeterminedbyﬁttingthedatatoa4-parameterlogisticequation.(C)DiagramsummarizingSARresults.Analoguesbasedonthe
L1 skeleton were obtained by structural modiﬁcations of the encircled substituents.332 dx.doi.org/10.1021/cb100314y |ACS Chem. Biol. 2011, 6, 325–335
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albeit at relatively modest levels. Notably, L29, the most potent
inhibitor in bacteria, was also most potent against RHBDL2
(Figure 5C).
We conclude that selected monocyclic β-lactams not only
are potent rhomboid inhibitors in vitro in the detergent micelle
environment where our screen was performed but also can
inhibit rhomboids in their native lipid membranes. Unlike
isocoumarins, the best β-lactams are selective for rhomboids
over chymotrypsin. Finally, our data show that monocyclic
β-lactams can inhibit diverse prokaryotic and eukaryotic rhom-
boids and also that their selectivity is tunable by chemical
modiﬁcation.
Mechanism of Action of β-Lactam Rhomboid Inhibitors.
Diverse β-lactams are inhibitors of several hydrolases, including
some soluble serine proteases (reviewed in ref 23). However,
rhomboids are evolutionarily unrelated to other proteases, and
much remains unknown about their enzymatic activity, so it is
impossible to predict with confidence the mechanism of their
inhibition by the compounds we have identified. To begin to
address this issue, we first tested whether inhibition was rever-
sible,byfollowingactivityrecoveryafterarapid100-folddilution
of the preincubated enzyme-inhibitor mixture into the reaction
buffer and 30 min recovery period.
27,28 We tested four β-lactams
(L19, L42,L43,andL45)withIC50<20μMagainstAarA,along
with DCI as a positive control. All behaved similarly to L42
(Figure 6A): we observed a partial and significant recovery of
activityafter100-folddilutionofenzymeandinhibitor(20-35%
activity of the DMSO control) but negligible recovery after 100-
fold dilution of the enzyme maintaining the initial inhibitor con-
centration (2-7% the activity of DMSO control), indicative of
partial or slow reversibility of inhibition. We also tested for time-
dependence of inhibition, which is typical of irreversible inhib-
itors.
23 Consistent with this idea, prolonging the preincubation
time of AarA and β-lactams led to progressively more potent
inhibitory effect (Figure 6B and data not shown). This point is
important because it means that the apparent IC50 values of the
inhibitors will strongly depend on the length of time of pre-
incubationwithrhomboid(FigureS2).TheIC50datareportedin
this paper all refer to 30 min preincubation.
Finally, to establish whether the inhibitors form covalent
complexes with rhomboid, to assess the stoichiometry of such
complexes, and to determine the possible speciﬁcity of this reac-
tion for the catalytic serine, we used MALDI-TOF mass spectro-
metry. We analyzed the inﬂuence of two of the most potent
β-lactam inhibitors of GlpG (L29 and L1) and an inactive
β-lactam (L30) on the mass of puriﬁed full-length GlpG and
its mutant form lacking the catalytic serine (S201A). In a proof-
of-principle experiment we showed that 3-fold stoichiometric
excess (100 μM) of the known mechanism-based isocoumarin
inhibitor JLK-6
29 generated a single adduct with wild-type GlpG
butnotwiththeS201Amutant(datanotshown).Usingthesame
experimental method, the β-lactams L29 and L1 caused a mass
shift of the enzyme peak that was approximately equal to their
molecular weight when incubated with wild-type GlpG but not
with the catalytic serine mutant S201A (Figure 6C and not
shown). Conversely, the β-lactam compound L30 that did not
inhibitGlpGinvitrohadnoeﬀectonthemassofeitherwild-type
or catalytic serine mutant of GlpG (Figure 6C). These results
demonstrate that monocyclic β-lactams inhibit rhomboid pro-
teases by speciﬁc covalent binding to their catalytic serine. At
present it is not clear whether the compounds L29 and L1 can
also bind to the catalytic histidine: although a doubly bound
adduct, with alkylation of the acyl enzyme intermediate through
the active site His, has been described for some β-lactams,
23 the
chemical structures of L29 and L1 suggest this to be unlikely.
Moreover, the slow reversibility of inhibition indicated by the
dilution assay rather suggests a single covalent link through the
catalytic serine.
23 Ad e ﬁnitive answer about the mechanism of
Figure5. Invivoactivityofβ-lactams.(A)InhibitionofendogenousGlpGbyL29inE.coliNR698carryingimp4213alleleandaplasmidexpressingthe
LacYTM2-based rhomboid substrate. Substrate (S) and product (P) were detected by Western blot with anti-Myc antibody, as described in Methods.
The E. coli NR698 (þ) or its ΔglpG variant (Δ) were grown in the presence of inhibitors at a range of concentrations and 2% DMSO. (B) The in vivo
EC50 values (μM, in brackets) of selected β-lactams were obtained from band quantiﬁcation performed as in Figure 4. Graph shows average data from
three experiments, with standard errors up to 20%. (C) Mouse RHBDL2 was inhibited in vivo by L29, but not L35 and L41 (tested at 10 and 30 μM).
COS7 cells were transfected with mRHBDL2 and Gurken substrate. Western blot was probed with anti-FLAG (Gurken) or anti-HA (mRHBDL2)
antibody. S and P represent the substrate and product band, respectively.333 dx.doi.org/10.1021/cb100314y |ACS Chem. Biol. 2011, 6, 325–335
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action will require more accurate mass data or a crystal structure
of the enzyme-inhibitor complex.
Concluding Remarks. Intramembrane proteases like rhom-
boids are increasingly understood to control many important
biological processes, but they are much less well characterized
than most protease families. Until now, no rhomboid inhibitors
have been identified, beyond a small number of broad-spectrum
serine protease inhibitors, notably isocoumarins, which have
weak inhibitory activity and high cytotoxicity. The monocyclic
β-lactam inhibitors that we have now identified provide exciting
starting points for further development of potent and specific
rhomboid inhibitors. Moreover, since many β-lactams are already
used as pharmaceuticals, these molecules may provide valuable
leads for future drug development.
’METHODS
Materials. Peptides were synthesized commercially, except for the
MCA-DNP modified Gurken, which was made in-house. Fluorescent
peptide KSp21 labeledwith darkquencherQSY21 andChromis-645-A-
PDA fluorescent dye (50 mg) was synthesized by Cambridge Research
Biochemicals (CRB). Dodecyl maltoside was from Glycon Biochemical
orAnatrace.E.coliNR698(MC4100imp4213)wasagenerousgiftfrom
Dr. Tom Silhavy, Princeton University, NJ, USA.
Figure 6. Mechanism of action of selected β-lactams. (A) Reversibility of L42 inhibition of AarA was tested using the 100-fold dilution technique
described in Results. Enzyme was incubated with inhibitor or DMSO for 30 min pre- and postdilution (to 71 nM ﬁnal concentration); residual activity
was thenassayed inthe presenceof600 nMKSp21substrate. (B)TheL42compound displaystime-dependentinhibitionofAarA.AarA(100nM)was
preincubated with 1-100 μM L42 for varying times (8-188 min), after which activity was measured using 600 nM KSp21 ﬂuorogenic substrate.
Activities were expressed relative to the solvent (DMSO) control. The inset shows a plot of1/kobs vs 1/[inhibitor concentration]
31. (C) The inhibitory
monocyclic β-lactamL29 formsa1:1 covalent complex withGlpG through itscatalyticserine. GlpG or itsS201A mutant(30μM) wereincubated with
the indicated compound (100 μM) for 30 min at 25 C, puriﬁed through a C4 ZipTip, and analyzed by MALDI-TOF mass spectrometry.334 dx.doi.org/10.1021/cb100314y |ACS Chem. Biol. 2011, 6, 325–335
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Recombinant Protein Expression and Purification. Bacterial
rhomboids (wild-type and its catalytic serine to alanine mutant) C-term-
inally His-tagged were expressed in E. coli C43(DE3),
30 isolated from
membranefraction,solubilizedindodecylmaltoside(DDM),andpurified
on a His-Pure Cobalt (ThermoScientific) affinity column. The column
waswashedwith10mMimidazolein20mMHepes-NaOH,0.3MNaCl,
10% (v/v) glycerol, 0.05% (w/v) DDM, pH 7.4. AarA and GlpG were
elutedat70and150mMimidazole,respectively.GurkenorLacYderived
chimeric substrates (MBP-TMD-Trx-His6
19) were overexpressed in
GlpG-deficient E. coli (MC4100 glpG::tet, strain KS52), which had been
generated by P1 phage mediated transduction of the glpG::tet allele
from E. coli GW338
21 onto a fresh MC4100 background. Overexpressed
chimericsubstrateswereisolatedfromthemembranefraction,solubilized
in DDM, and purified on a His-Pure column (wash buffer, elution buffer
andstripbufferat25,70,and150mMimidazole,respectively),exceptthat
GurkenTMDfusionwasfurtherpurifiedonamyloseresin(NewEngland
Biolabs).
In Vitro Fluorescent Assay, HTS, and Counter-screen.
Rhomboid protease assay was performed at 24-25 C in Nunc White
384-wellplates(VWR)inafinalreactionvolumeof20μL.Eachreaction
contained the following final concentration of reagents: 25 mM Hepes
pH 7.4, 5 mM EDTA, 5% (v/v) glycerol, 0.5% (w/v) DDM, 20% (v/v)
DMSO, 100 nM rhomboid AarA or 37 nM chymotrypsin (Sigma), and
600nMofrhomboidfluorescentpeptidesubstrate.Importantly,increas-
ing the DMSO concentration from 5% to 20% led to a linear increase in
the cleavage rate of KSp21, suggesting that DMSO did not compromise
AarAfunctioninthisconcentrationrange.UsingBiomekFX(Beckman-
Coulter) robotics, 8 μL of enzyme mix (reaction buffer, DDM, AarA, or
enzyme buffer) was first added in each well, then 2 μL of 200 μM
compound or DMSO only. All compounds were preincubated with the
rhomboid enzyme for 30 min at 25 C to accommodate any slow-
bindingeffectors,andthereactionwasstartedbytheadditionof10μLof
peptide mix (reaction buffer, DDM, DMSO, peptide) using a Flexdrop
liquid dispenser (Perkin-Elmer). After 50-60 min, the reaction was
stopped, whilestill in thelinear phase, with 4μLof1M phosphoric acid
pH 1.5 on a WellMate (ThermoScientific). Fluorescence intensity was
detected using a Pherastar plate reader (BMG-Labtech) with excitation
at640nmandemissionat680nm.Afterscreening57,703 syntheticand
natural compounds, we identified 162 hits, applying a cutoff at 80% (or
120%) activity of DMSO high control activity for hit confirmation and
counter-screening. Counter-screen consisted of adding the compounds
after the reaction was completed to identify compounds that interfered
with the fluorescent signal, independent of rhomboid inhibition.
Chemical Synthesis. For variation of the bis-CF3 aryl ring por-
tion, the appropriate aniline was coupled with commercially available
3,3,3-trifluoro-2-(trifluoromethyl)propionic acid under nonbasic condi-
tions. Noncommercial anilines were accessed by standard functional
group transformations of nitro compounds, followed by reduction.
Replacements forthebis-CF3groupwerepreparedbycouplingwiththe
appropriate acid, followed by further transformations where necessary.
Most β-lactams were prepared by N-sulfonylation of commercially
available 4-phenylazetidine-2-one. Non-commercial C-4-substituted
analogues were accessed by ring closure of the corresponding β-amino
acids, followed by N-sulfonylation. Compounds with an amide at C-3
were prepared from N-protected DL-serine by ring closure of the
N-methoxyamide, conversion to the N-sulfonyl β-lactam, deprotection
of the C-3 amino group, and treatment with the acid chloride or acid
under standard conditions. Open chain analogues were prepared by
means of standard transformations on the corresponding amino acids.
InVitroGel-BasedAssay. Activityofthebesthitswasassessedin
an independent in vitro assay using purified recombinant protein
substrates(MBP-TMD-Trx-His6,withLacYorGurkenTMD)followed
by SDS-PAGE analysis of the cleavage products, as reported previ-
ously.
19Atypical20μLreaction,runat37Cfor60-75min,contained
25 mM Hepes-NaOH pH 7.4, 5 mM EDTA, 5% (v/v) glycerol, 0.05%
(w/v)DDM,0.4M(forGlpG)or0.1M(forAarA)NaCl,3μMchimeric
protein substrate, 320 nM GlpG or 700 nM AarA, and 5% (v/v) DMSO.
All compounds were preincubated with the enzymes for 30 min at 25 C.
In Vivo Assay in Bacteria. The glpG::tet disruption allele from E.
coliGW338
21wastransferredintoE.coliNR698genomeusingP1phage
transduction to generate strain KS69 (ΔglpG), which was selected and
maintained on 5 μg/mL tetracycline. Both NR698 and KS69 were elec-
troporated with pGW93 encoding β-lactamase-LacYTM2-MBP-His6-
Myc chimera
21 and selected on 50 μg/mL spectinomycin. NR698 and
KS59 carrying pGW93 were grown overnight at 37 C with 50 μg/mL
spectinomycin and 5 μg/mL tetracycline. The next day, 1.5 mL of fresh
LB medium was inoculated with 1/100 (NR698) or 1/33 (KS69) of
overnight culture in the presence of spectinomycin. After ∼2 h at 37 C
or when OD600 nm reached 0.3-0.4 absorbance unit, 150 μL was trans-
ferred to clean tubes, and 3 μL of DMSO or 1-100 μM β-lactam was
added(2%(v/v)DMSOthroughout).After15minatRT,eachtubewas
supplemented with 1 mM cAMP and 1 mM IPTG, and culture was
maintained at 25 C, 1200 rpm, for 1 h for recombinant protein expres-
sion.
21 Bacterial cells were collected by centrifugation, and pellets were
dissolved in SDS-PAGE sample buffer. After electrophoresis on 4-20%
Bis-Tris gradient gel (Invitrogen), samples were transferred to PVDF
Immobilon-P membrane (Millipore), and protein loading and transfer
efficiency were checked by Ponceau red staining. Myc-tagged proteins
werevisualizedbyanti-Mycprimary(1:900c-Myc(A-14):sc-789,Santa-
Cruz Biotechnology, Inc.) and anti rabbit-HRP conjugate secondary
antibodies and detected by enhanced chemiluminescence (GE
Healthcare).
In Vivo Assay in Mammalian Cells. COS7 cells were trans-
fected in 24-well plates with 20 ng of HA-tagged mouse RHBDL2-
KDEL (RHBDL2) plasmid, 50 ng of FLAG-tagged Gurken substrate
construct, and pcDNA3 vector up to a total amount of 200 ng DNA per
well using Fugene6 (Roche). Inhibitors (dissolved in DMSO) were
added 2 h post transfection to final concentrations of 10 and 30 μM and
1% (v/v) DMSO. Twelvehours post transfection, cells were lysed in 1X
SDS-PAGE sample buffer, and proteins were separatedon a 4-20% Tris-
glycinegradientgel(Invitrogen).ProcessingofGurkenbyRHBDL2was
analyzed by Western Blot using HRP-conjugated anti-FLAG (Sigma)
antibody for Gurken detection and HRP-conjugated anti-HA antibody
(Covance) for RHBDL2 detection.
Mass Spectrometry. Purified full-length C-terminally His-tagged
GlpG
20 and its active site mutant S201A (30 μM) were incubated with
100 μM inhibitor for 30 min at 25 C in a buffer of pH 7.5 containing
20mMHEPES,0.05%(w/v) dodecylmaltoside,100mMNaCl,10%(v/v)
glycerol, and 5% (v/v) dimethylsulfoxide (DMSO). Samples were
adjusted to 0.1% (v/v) trifluoroacetic acid (TFA) and purified using a
C4 ZipTip (Millipore) according to manufacturer’s instructions, eluting
into 5 μL of 10 mg/mL R-cyano-4-hydroxycinnamic acid (CHCA,
Sigma) matrixdissolvedin50%(v/v) acetonitrileinwaterand0.05%(v/v)
TFA. The ZipTip eluates were spotted onto a thin layer of CHCA and
immediately analyzed by MALDI-TOF mass spectrometry on a Voyager-
DE PRO in linear positive mode with external mass calibration on
bovineinsulin,E.colithioredoxin,andhorseapomyoglobin(Calibration
Mixture 3, Applied Biosystems).
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